Contrast of medical and nonmedical use of stimulant drugs, basis for the distinction, and risk of addiction: Comment on smith and farah (2011)

Psychological Bulletin

Volumn 137, Issue 5, 2011, Pages 742-748

  Swanson, James M ^a,b   Wigal, Timothy L ^b   Volkow, Nora D ^c  

^a FLORIDA INTERNATIONAL UNIVERSITY   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c NATIONAL INSTITUTE ON DRUG ABUSE   (United States)

Author keywords

Addiction to stimulants; ADHD; Diversion of stimulants; Medical use of stimulants; Stimulant drugs

Indexed keywords

CENTRAL STIMULANT AGENT; PRESCRIPTION DRUG;

COGNITION; DRUG EFFECT; HUMAN; INTELLIGENCE; NOTE; OFF LABEL DRUG USE; STATISTICS;

CENTRAL NERVOUS SYSTEM STIMULANTS; COGNITION; HUMANS; INTELLIGENCE; OFF-LABEL USE; PRESCRIPTION DRUGS;

EID: 80052196380     PISSN: 00332909     EISSN: None     Source Type: Journal    
DOI: 10.1037/a0024898     Document Type: Note

References (48)

1. Advokat C. What are the cognitive effects of stimulant medications? Emphasis on adults with attention-deficit/hyperactivity disorder (ADHD). Neuroscience and Biobehavioral Reviews 2010, 34:1256-1266. 10.1016/j.neubiorev.2010.03.006.
2. American Psychiatric Association Diagnostic and statistical manual of mental disorders 1994, Author, Washington, DC. 4th ed.
3. Barbaresi W.J., Katusic S.K., Colligan R.C., Weaver A.L., Jacobsen S.J. Modifiers of long-term school outcomes for children with attention-deficit/hyperactivity disorder: Does treatment with stimulant medication make a difference? Results from a population-based study. Journal of Developmental and Behavioral Pediatrics 2007, 28:274-287. 10.1097/DBP.0b013e3180cabc28.
4. Barkley R.A. Behavioral inhibition, sustained attention, and executive functions: Constructing a unifying theory of ADHD. Psychological Bulletin 1997, 121:65-94. 10.1037/0033-2909.121.1.65.
5. Berman S.M., Kuczenski R., McCracken J.T., London E.D. Potential adverse effects of amphetamine treatment on brain and behavior: A review. Molecular Psychiatry 2009, 14:123-142. 10.1038/mp.2008.90.
6. Conners C.K. Forty years of methylphenidate treatment in attention-deficit/hyperactivity disorder. Journal of Attention Disorders 2002, 6:S17-S30.
7. Desantis A.D., Hane A.C. " Adderall is definitely not a drug": Justifications for the illegal use of ADHD stimulants. Substance Use & Misuse 2010, 45:31-46. 10.3109/10826080902858334.
8. Faraone S.V., Glatt S.J. A comparison of the efficacy of medications for adult attention-deficit/hyperactivity disorder using meta-analysis of effect sizes. Journal of Clinical Psychiatry 2010, 71:754-763. 10.4088/JCP.08m04902pur.
9. Ghodse H. " Uppers" keep going up. British Journal of Psychiatry 2007, 191:279-281. 10.1192/bjp.bp.107.035212.
10. Grant B.F., Dawson D.A. Age at onset of alcohol use and its association with DSM-IV alcohol abuse and dependence: Results from the National Longitudinal Alcohol Epidemiologic Survey. Journal of Substance Abuse 1997, 9:103-110. 10.1016/S0899-3289(97)90009-2.
11. Greenhill L.L., Swanson J.M., Vitiello B., Davies M., Clevenger W., Wu M., Wigal T. Impairment and deportment responses to different methylphenidate doses in children with ADHD: The MTA titration trial. Journal of the American Academy of Child & Adolescent Psychiatry 2001, 40:180-187. 10.1097/00004583-200102000-00012.
12. Grinspoon L., Hedblom P. The speed culture: Amphetamine use and abuse in America 1975, Harvard University Press, Cambridge, MA.
13. Hellwig-Brida S., Daseking M., Keller F., Peterman F., Goldbeck L. Methylphenidate on intelligence and attention components in boys with attention-deficit/hyperactivity disorder. Journal of Child & Adolescent Psychopharmacology 2011, 21:245-253. 10.1089/cap.2010.0041.
14. Illes J., Sahakian B.J. The Oxford handbook of neuroethics 2011, Oxford University Press, Oxford, England.
15. Individuals With Disabilities Education Act, Pub. L. No. 101-476, 104 Stat. 1142 (1990).
16. International Narcotics Control Board Psychotropic substances: Statistics for 1996 to 2009 2009, United Nations, New York, NY.
17. Kessler R.C., Adler L., Barkley R., Biederman J., Conners C.K., Demler O., Zaslavsky A.M. The prevalence and correlates of adult ADHD in the United States: Results from the National Comorbidity Survey Replication. American Journal of Psychiatry 2006, 163:716-723. 10.1176/appi.ajp.163.4.716.
18. Kroutil L.A., Van Brunt D.L., Herman-Stahl M.A., Heller D.C., Bray B.M., Penne M.A. Nonmedical use of prescription stimulants in the United States. Drug and Alcohol Dependence 2006, 84:135-143. 10.1016/j.drugalcdep.2005.12.011.
19. Marcus S.C., Durkin M. Stimulant adherence and academic performance in urban youth with attention-deficit/hyperactivity disorder. Journal of the American Academy of Child & Adolescent Psychiatry 2011, 50:480-489. 10.1016/j.jaac.2011.02.007.
20. Molina B.S., Hinshaw S.P., Swanson J.M., Arnold L.E., Vitiello B., Jensen P.S., the MTA Cooperative Group The MTA at 8 years: Prospective follow-up of children treated for combined-type ADHD in a multisite study. Journal of the American Academy of Child & Adolescent Psychiatry 2009, 48:484-500. 10.1097/CHI.0b013e31819c23d0.
21. MTA Cooperative Group A 14-month randomized clinical trial of treatment strategies for attention deficit hyperactivity disorder. Archives of General Psychiatry 1999, 56:1073-1086. 10.1001/archpsyc.56.12.1073.
22. Pennington B.F., Ozonoff S. Executive functions and developmental psychopathology. Journal of Child Psychology and Psychiatry 1996, 37:51-87. 10.1111/j.1469-7610.1996.tb01380.x.
23. Pietrzak R.H., Mollica C.M., Maruff P., Snyder P.J. Cognitive effects of immediate-release methylphenidate in children with attention-deficit/hyperactivity disorder. Neuroscience and Biobehavioral Reviews 2006, 30:1225-1245. 10.1016/j.neubiorev.2006.10.002.
24. Polderman T.J.C., Derks E.M., Hudziak J.J., Verhulst F.C., Posthuma D., Boomsma D.I. Across the continuum of attention skills: A twin study of the SWAN ADHD Rating Scale. Journal of Child Psychology and Psychiatry 2007, 48:1080-1087. 10.1111/j.1469-7610.2007.01783.x.
25. Rasmussen N. On speed 2008, New York University Press, New York, NY.
26. Sahakian B., Morein-Zamir S. Professor's little helper. Nature 2007, December 20, 450:1157-1159. 10.1038/4501157a.
27. Santosh P.J., Taylor E., Swanson J.M., Wigal T., Chuang S., Davies M., Posner M. Refining the diagnosis of inattention and overactivity syndrome: A reanalysis of the multimodal treatment study of attention deficit/hyperactivity disorder (ADHD) based on ICD-10 criteria for hyperkinetic disorder. Clinical Neuroscience Research 2005, 5:307-314. 10.1016/j.cnr.2005.09.010.
28. Scheffler R.M., Brown T., Fulton B., Hinshaw S.P., Levine P., Stone S.I. Positive association between ADHD medication use and academic achievement during elementary school. Pediatrics 2009, 123:1273-1279. 10.1542/peds.2008-1597.
29. Smith M.E., Farah M.J. Are prescription stimulants " smart pills" ? The epidemiology and cognitive neuroscience of prescription stimulant use by normal healthy individuals. Psychological Bulletin 2011, 137:717-741. 10.1037/a0023825.
30. Stix G. Turbocharging the brain: Pills to make you smarter?. Scientific American 2009, October, 301(4):46-55.
31. Substance Abuse and Mental Health Services Administration Results from the 2008 National Survey on Drug Use and Health: National findings 2009, Office of Applied Studies, Rockville, MD, (NSDUH Series H-36, HHS Publication No. SMA 09-4434).
32. Swanson J., Deutsch C., Cantwell D., Posner M., Kennedy J., Barr C., Wasdell M. Genes and attention-deficit hyperactivity disorder. Clinical Neuroscience Research 2001, 1:207-216. 10.1016/S1566-2772(01)00007-X.
33. Swanson J.M., Baler R.D., Volkow N.D. Understanding the effects of stimulant medications on cognition in individuals with attention-deficit hyperactivity disorder: A decade of progress. Neuropsychopharmacology 2011, 36:207-226. 10.1038/npp.2010.160.
34. Swanson J.M., Lerner M., Williams L. More frequent diagnosis of attention deficit-hyperactivity disorder. New England Journal of Medicine 1995, 333:944. 10.1056/NEJM199510053331419.
35. Swanson J.M., McBurnett K., Wigal T., Pfiffner L.J., Lerner M.A., Williams L., Fisher T.D. Effect of stimulant medication on children with attention deficit disorder: A " review of reviews." Exceptional Children 1993, 60:154-161.
36. Swanson J.M., Volkow N.D. Increasing use of stimulants warns of potential abuse. Nature 2008, May 29, 453:586. 10.1038/453586a.
37. Swanson J.M., Volkow N.D. Psychopharmacology: Concepts and opinions about the use of stimulant medications. Journal of Child Psychology and Psychiatry 2009, 50:180-193. 10.1111/j.1469-7610.2008.02062.x.
38. Swanson J.M., Wigal T., Lakes K. DSM-V and the future diagnosis of attention-deficit/hyperactivity disorder. Current Psychiatry Reports 2009, 11:399-406. 10.1007/s11920-009-0060-7.
39. Swanson J.M., Wigal T., Lakes K., Volkow N.D. Attention deficit hyperactivity disorder: Defining a spectrum disorder and considering neuroethical implications. The Oxford handbook of neuroethics 2011, 309-342. Oxford University Press, Oxford, England. J. Illes, B.J. Sahakian (Eds.).
40. Teter C.J., McCabe S.E., LaGrange K., Cranford J.A., Boyd C.J. Illicit use of specific prescription stimulants among college students: Prevalence, motives, and routes of administration. Pharmacolotherapy 2006, 26:1501-1510.
41. Turner D.C., Blackwell A.D., Dowson J.H., McLean A., Sahakian B.J. Neurocognitive effects of methylphenidate in adult attention-deficit/hyperactivity disorder. Psychopharmacology 2005, 178:286-295. 10.1007/s00213-004-1993-5.
42. U.S.Census Bureau Annual estimates of the resident population by sex and five-year age groups for the United States, April 1, 2004 to July 1, 2009 (NC-EST2009-01) http://www.census.gov/popest/states/NST-ann-est.html.
43. U.S.Food and Drug Administration Current drug shortages http://www.fda.gov/Drugs/DrugSafety/DrugShortages/ucm050792.htm.
44. Visser S.N., Bitsko R.H., Danielson M.L., Perou R. Increasing prevalence of parent-reported attention-deficit hyperactivity disorder among children-United States, 2003 and 2007. Morbidity and Mortality Weekly Report 2010, 59:1439-1443.
45. Volkow N.D., Swanson J.M. The action of enhancers can lead to addiction. Nature 2008, January 31, 451:520. 10.1038/451520a.
46. Volkow N.D., Wang G.-J., Fowler J.S., Telang F., Maynard L., Logan J., Swanson J.M. Evidence that methylphenidate enhances the saliency of a mathematical task by increasing dopamine in the human brain. American Journal of Psychiatry 2004, 161:1173-1180. 10.1176/appi.ajp.161.7.1173.
47. Volkow N.D., Wang G.-J., Kollins S.H., Wigal T.L., Newcorn J.H., Telang F., Swanson J.M. Evaluating dopamine reward pathway in ADHD: Clinical implications. JAMA 2009, 302:1084-1091. 10.1001/jama.2009.1308.
48. World Health Organization International classification of diseases 1994, Author, Geneva, Switzerland. 10th revision.